Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Document Type
- Journal article (14)
Language
- English (14) (remove)
Keywords
- CXCR4 (3)
- chemokine receptor (3)
- positron emission tomography (3)
- HNSCC (2)
- in vivo imaging (2)
- lymphoma (2)
- microenvironment (2)
- mutations (2)
- Activation (1)
- Bruton Tyrosine Kinase (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- CXCR4/SDF-1 (1)
- DEL(5Q) (1)
- DLBCL (1)
- DOTATOC (1)
- EGFR (1)
- FDG PET/CT (1)
- FLT-PET (1)
- Ibrutinib (1)
- Ligand (1)
- MDS (1)
- MYC (1)
- Malignancies (1)
- Multiple Myeloma (1)
- NF-KAPPA-B (1)
- PCI-32765 (1)
- PET/CT (1)
- PRRT (1)
- Pathway (1)
- Positronen-Emissions-Tomografie (1)
- Proliferation (1)
- Rho-GTPases (1)
- SSTR (1)
- SphK1 (1)
- TP53 mutations (1)
- Targeted Therapies (1)
- Tumor Microenvironment (1)
- USP9X (1)
- XIAP (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- activation (1)
- acute myeloid leukemia (1)
- apoptosis (1)
- apoptosis, Myc (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autologous transplantation (1)
- azacitidine (1)
- bone disease (1)
- cancer (1)
- cancer genetics (1)
- cancer genomics (1)
- cancer therapy (1)
- cells (1)
- cetuximab (1)
- chemokine receptor-4 (1)
- cleavage (1)
- combined immunodeficiency (1)
- cycle (1)
- endothelial cells (1)
- glioblastoma (1)
- glutaminase inhibition (1)
- growth (1)
- helper T-cells (1)
- imaging (1)
- involvement (1)
- karyotype (1)
- leukemia (1)
- lymphoid-tissue (1)
- malignancies (1)
- messenger RNA (1)
- mice (1)
- mitosis (1)
- multiple myeloma (1)
- myeloma (1)
- neuroendocrine tumor (1)
- niche (1)
- p53 expression (1)
- peptide receptor radionuclide therapy (1)
- positron emission tomography/computed tomography (1)
- prognosis (1)
- prognostic value (1)
- radiation (1)
- radiation-induced migration (1)
- roquin (1)
- scoring system (1)
- stem-cells (1)
- survival (1)
- target (1)
- therapeutic target (1)
- translational research (1)
- ubiquitin (1)
Institute
- Pathologisches Institut (14) (remove)
Objectives: The aim of this study was to evaluate the efficiency of cetuximab-based anti-EGFR treatment and Aurora kinase A / B knockdown as a function of Aurora kinase polymorphism in HNSCC cell lines.
Materials and methods: First, protein expression of Aurora kinase A / B and EGFR and Aurora kinase A polymorphism were studied in tumour samples.
The survival and proliferation of Aurora kinase A homo- (Cal27) and heterozygous (HN) HNSCC cell lines was evaluated using a colony formation assay and a flow cytometric assay. Also, aneuploidy was determined. EGFR signalling pathway were visualised by western blotting.
Results: Immunohistochemistry revealed the overexpression of Aurora kinase A / B in HNSCC. The knockdown of each kinase caused a significant decrease in clonogenic survival, independent of Aurora kinase A polymorphism. In contrast, cetuximab treatment impaired clonogenic survival only in the Aurora kinase A-homozygous cell line (Cal27).
Conclusion: This study provides in vitro evidence for the predictive value of Aurora kinase A polymorphism in the efficiency of cetuximab treatment. Resistance to cetuximab treatment can be overcome by simultaneous Aurora kinase A/B knockdown.
Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure.
The paracaspase Malt1 is a central regulator of antigen receptor signaling that is frequently mutated in human lymphoma. As a scaffold, it assembles protein complexes for NF-kappa B activation, and its proteolytic domain cleaves negative NF-kappa B regulators for signal enforcement. Still, the physiological functions of Malt1-protease are unknown. We demonstrate that targeted Malt1-paracaspase inactivation induces a lethal inflammatory syndrome with lymphocyte-dependent neurodegeneration in vivo. Paracaspase activity is essential for regulatory T cell (Treg) and innate-like B cell development, but it is largely dispensable for overcoming Malt1-dependent thresholds for lymphocyte activation. In addition to NF-kappa B inhibitors, Malt1 cleaves an entire set of mRNA stability regulators, including Roquin-1, Roquin-2, and Regnase-1, and paracaspase inactivation results in excessive interferon gamma (IFN gamma) production by effector lymphocytes that drive pathology. Together, our results reveal distinct threshold and modulatory functions of Malt1 that differentially control lymphocyte differentiation and activation pathways and demonstrate that selective paracaspase blockage skews systemic immunity toward destructive autoinflammation.